Пожалуйста, используйте этот идентификатор, чтобы цитировать или ссылаться на этот ресурс: http://elar.urfu.ru/handle/10995/101482
Название: HIV/SARS-CoV-2 coinfection: A global perspective
Авторы: Kanwugu, O. N.
Adadi, P.
Дата публикации: 2021
Издатель: John Wiley and Sons Inc
Библиографическое описание: Kanwugu O. N. HIV/SARS-CoV-2 coinfection: A global perspective / O. N. Kanwugu, P. Adadi. — DOI 10.1002/jmv.26321 // Journal of Medical Virology. — 2021. — Vol. 93. — Iss. 2. — P. 726-732.
Аннотация: Since its first appearance in Wuhan, China, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has rapidly spread throughout the world and has become a global pandemic. Several medical comorbidities have been identified as risk factors for coronavirus disease 2019 (COVID-19). However, it remains unclear whether people living with human immunodefeciency virus (PLWH) are at an increased risk of COVID-19 and severe disease manifestation, with controversial suggestion that HIV-infected individuals could be protected from severe COVID-19 by means of antiretroviral therapy or HIV-related immunosuppression. Several cases of coinfection with HIV and SARS-CoV-2 have been reported from different parts of the globe. This review seeks to provide a holistic overview of SARS-CoV-2 infection in PLWH. © 2020 Wiley Periodicals LLC
Ключевые слова: ANTIRETROVIRAL THERAPY/COINFECTION
COVID-19
HIV
IMMUNODEFICIENCY
CLINICAL FEATURE
COMORBIDITY
CORONAVIRUS DISEASE 2019
DISEASE ASSOCIATION
DISEASE SEVERITY
HIGH INCOME COUNTRY
HUMAN
HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION
INFECTION RISK
MIXED INFECTION
NONHUMAN
PANDEMIC
REVIEW
VIRUS LOAD
ADULT
CD4+ T LYMPHOCYTE
DIABETES MELLITUS
DRUG EFFECT
FEMALE
GROWTH, DEVELOPMENT AND AGING
HIGHLY ACTIVE ANTIRETROVIRAL THERAPY
HUMAN IMMUNODEFICIENCY VIRUS
HUMAN IMMUNODEFICIENCY VIRUS INFECTION
HYPERTENSION
IMMUNOCOMPROMISED PATIENT
IMMUNOLOGY
MALE
MIDDLE AGED
MIXED INFECTION
MORTALITY
PANDEMIC
PATHOGENICITY
PATHOPHYSIOLOGY
SURVIVAL ANALYSIS
TREATMENT OUTCOME
VIROLOGY
ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT
ADULT
ANTI-HIV AGENTS
ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE
CD4-POSITIVE T-LYMPHOCYTES
COINFECTION
COMORBIDITY
COVID-19
DIABETES MELLITUS
FEMALE
HIV
HIV INFECTIONS
HUMANS
HYPERTENSION
IMMUNOCOMPROMISED HOST
MALE
MIDDLE AGED
PANDEMICS
SARS-COV-2
SURVIVAL ANALYSIS
TREATMENT OUTCOME
URI: http://elar.urfu.ru/handle/10995/101482
Условия доступа: info:eu-repo/semantics/openAccess
Идентификатор РИНЦ: 45488979
Идентификатор SCOPUS: 85088583592
Идентификатор WOS: 000552989400001
Идентификатор PURE: 20377699
51bf165d-0ab5-4bcc-a955-a0fad89dc5b3
ISSN: 1466615
DOI: 10.1002/jmv.26321
Располагается в коллекциях:Научные публикации ученых УрФУ, проиндексированные в SCOPUS и WoS CC

Файлы этого ресурса:
Файл Описание РазмерФормат 
2-s2.0-85088583592.pdf1,12 MBAdobe PDFПросмотреть/Открыть


Все ресурсы в архиве электронных ресурсов защищены авторским правом, все права сохранены.